BR112017013595A2 - cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina. - Google Patents
cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina.Info
- Publication number
- BR112017013595A2 BR112017013595A2 BR112017013595A BR112017013595A BR112017013595A2 BR 112017013595 A2 BR112017013595 A2 BR 112017013595A2 BR 112017013595 A BR112017013595 A BR 112017013595A BR 112017013595 A BR112017013595 A BR 112017013595A BR 112017013595 A2 BR112017013595 A2 BR 112017013595A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- recombinant
- bird
- expression cassette
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16341—Use of virus, viral particle or viral elements as a vector
- C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/34—Vector systems having a special element relevant for transcription being a transcription initiation element
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção se refere a uma vacina de nd-ibd vetorizada com hvt nova e melhorada compreendendo um hvt recombinante compreendendo o gene vp2 de ibdv e o gene f de ndv a um alvo animal. o hvt recombinante pode ser usado em uma vacina para aves, que apresenta boa replicação viral do vetor, efetiva expressão do gene f de ndv e vp2 de ibdv, imunoproteção melhorada contra nd e ibd e estabilidade genética melhorada sobre os construtos do estado da técnica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14200340 | 2014-12-24 | ||
PCT/EP2015/081121 WO2016102647A1 (en) | 2014-12-24 | 2015-12-23 | Improved hvt-vectored nd-ibd vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017013595A2 true BR112017013595A2 (pt) | 2018-03-06 |
Family
ID=52282550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017013595A BR112017013595A2 (pt) | 2014-12-24 | 2015-12-23 | cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina. |
Country Status (12)
Country | Link |
---|---|
US (1) | US10308956B2 (pt) |
EP (1) | EP3185899B1 (pt) |
JP (1) | JP6246985B1 (pt) |
CN (1) | CN107002097B (pt) |
AR (1) | AR103245A1 (pt) |
BR (1) | BR112017013595A2 (pt) |
ES (1) | ES2648672T3 (pt) |
HU (1) | HUE035364T2 (pt) |
MX (1) | MX2017008504A (pt) |
PL (1) | PL3185899T3 (pt) |
RU (1) | RU2692013C2 (pt) |
WO (1) | WO2016102647A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE061405T2 (hu) | 2016-06-17 | 2023-06-28 | Intervet Int Bv | Nem patogén Marek-betegség vírus konstruktok, amelyek fertõzõ laryngotracheitis vírus és fertõzõ bursitis vírus antigéneket kódolnak |
EP3554536B1 (en) | 2016-12-14 | 2022-10-26 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant hvt vectors expressing multiple antigens of avian pathogens, and vaccines comprising them |
CN107099513B (zh) * | 2017-06-22 | 2020-07-14 | 北京邦卓生物科技有限公司 | 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用 |
WO2019072964A1 (en) | 2017-10-12 | 2019-04-18 | Intervet International B.V. | RECOMBINANT NON-PATHOGENIC MAREK DISEASE VIRUS CONSTRUCTS ENCODING MULTIPLE HETEROLOGOUS ANTIGENS |
JP7448475B2 (ja) | 2017-12-20 | 2024-03-12 | インターベット インターナショナル ベー. フェー. | 細胞関連アルファヘルペスウイルスワクチン用の改善された希釈液 |
CN109320594B (zh) * | 2018-11-13 | 2021-09-28 | 四川大学 | 一种禽传染性支气管炎和新城疫的病毒样颗粒、制备方法及应用 |
CN110331135A (zh) * | 2019-07-18 | 2019-10-15 | 扬州大学 | 表达基因vii型新城疫病毒融合蛋白的重组火鸡疱疹病毒候选疫苗株及制备方法 |
EP4028510A1 (en) | 2019-09-11 | 2022-07-20 | Zoetis Services LLC | Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof |
BR112022010825A2 (pt) | 2019-12-20 | 2022-08-23 | Intervet Int Bv | Vacina de vetor hvt multivalente |
BR112022025733A2 (pt) | 2020-06-17 | 2023-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Vetores hvt recombinantes expressando hemaglutinina de influenza e composições imunogênicas, e produção e usos dos mesmos |
JP2023539771A (ja) | 2020-09-07 | 2023-09-19 | インターベット インターナショナル ベー. フェー. | Ha抗体陽性ターゲットのためのhaステムワクチン |
CN112501139B (zh) * | 2020-12-11 | 2023-03-21 | 新乡学院 | 一株重组新城疫病毒毒株及其制备方法和应用 |
WO2022136623A1 (en) | 2020-12-24 | 2022-06-30 | Intervet International B.V. | Multivalent hvt vector vaccine |
WO2023213946A1 (en) | 2022-05-05 | 2023-11-09 | Intervet International B.V. | New multivalent hvt vector vaccine |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5961982A (en) | 1985-09-06 | 1999-10-05 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
US5965138A (en) | 1985-09-06 | 1999-10-12 | Syntro Corporation | Recombinant chimeric virus and uses thereof |
US5928648A (en) | 1985-09-06 | 1999-07-27 | Syntro Corporation | Recombinant herpesvirus of turkeys and uses thereof |
AU623333B2 (en) * | 1986-01-27 | 1992-05-14 | Syntro Corporation | Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same |
GB8603341D0 (en) | 1986-02-11 | 1986-03-19 | Portapax Ltd | Foam sheet |
EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
FR2728795B1 (fr) | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire |
DE69836557T2 (de) | 1997-10-03 | 2007-09-20 | Zeon Corp. | Rekombinanten des infektiösen vogel-herpesvirus und rekombinante impfstoffe, die unter dessen verwendung hergestellt wurden |
US6764684B2 (en) | 2001-09-28 | 2004-07-20 | Zeon Corporation | Avian herpesvirus-based recombinant infectious bursal disease vaccine |
BRPI0913216A2 (pt) | 2008-06-23 | 2016-01-19 | Intervet Int Bv | uso de um herpesvírus recombinante de perus, e, herpesvírus recombinante de perus. |
BR112014008161A2 (pt) * | 2011-10-21 | 2017-04-11 | Intervet Int Bv | vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas |
TR201818883T4 (tr) | 2011-10-21 | 2019-01-21 | Intervet Int Bv | Enfeksiyöz laringotrakeit virüsü ve Newcastle hastalığı virüsü antijenlerini kodlayan rekombinant patojenik olmayan marek hastalığı virüsü yapıları. |
US9114108B2 (en) | 2011-11-30 | 2015-08-25 | Merial, Inc. | Recombinant HVT vectors expressing antigens of avian pathogens and uses thereof |
IN2014CN04833A (pt) * | 2011-11-30 | 2015-09-18 | Merial Ltd | |
EP2644702A1 (en) * | 2012-03-30 | 2013-10-02 | Ceva Sante Animale | Multivalent recombinant avian herpes virus and vaccine for immunizing avian species |
US10428316B2 (en) | 2014-12-04 | 2019-10-01 | Intervet Inc. | Immortalised chicken embryo fibroblasts |
-
2015
- 2015-12-22 AR ARP150104255A patent/AR103245A1/es unknown
- 2015-12-23 EP EP15817860.8A patent/EP3185899B1/en active Active
- 2015-12-23 CN CN201580070228.0A patent/CN107002097B/zh active Active
- 2015-12-23 ES ES15817860.8T patent/ES2648672T3/es active Active
- 2015-12-23 BR BR112017013595A patent/BR112017013595A2/pt unknown
- 2015-12-23 RU RU2017126030A patent/RU2692013C2/ru active
- 2015-12-23 US US15/110,628 patent/US10308956B2/en active Active
- 2015-12-23 PL PL15817860T patent/PL3185899T3/pl unknown
- 2015-12-23 WO PCT/EP2015/081121 patent/WO2016102647A1/en active Application Filing
- 2015-12-23 JP JP2017533847A patent/JP6246985B1/ja active Active
- 2015-12-23 HU HUE15817860A patent/HUE035364T2/en unknown
- 2015-12-23 MX MX2017008504A patent/MX2017008504A/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
WO2016102647A1 (en) | 2016-06-30 |
US20170306353A1 (en) | 2017-10-26 |
RU2017126030A (ru) | 2019-01-24 |
AR103245A1 (es) | 2017-04-26 |
ES2648672T3 (es) | 2018-01-05 |
CN107002097B (zh) | 2021-06-15 |
EP3185899A1 (en) | 2017-07-05 |
MX2017008504A (es) | 2017-10-11 |
RU2692013C2 (ru) | 2019-06-19 |
JP6246985B1 (ja) | 2017-12-13 |
US10308956B2 (en) | 2019-06-04 |
RU2017126030A3 (pt) | 2019-01-24 |
JP2018501792A (ja) | 2018-01-25 |
CN107002097A (zh) | 2017-08-01 |
HUE035364T2 (en) | 2018-05-02 |
EP3185899B1 (en) | 2017-10-18 |
PL3185899T3 (pl) | 2018-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017013595A2 (pt) | cassete de expressão de dna recombinante, molécula de dna recombinante, vírus herpes de peru recombinante, célula hospedeira, métodos para construção de um vírus herpes de peru recombinante, para preparação de uma vacina, para prevenir ou reduzir infecção por vírus da doença bursal infecciosa e/ou vírus da doença de newcastle ou sinais associados de doença e para vacinação das aves, vacina para aves, e, usos de um cassete de expressão e de uma vacina. | |
Sun et al. | H9N2 influenza virus in China: a cause of concern | |
Li et al. | Avian influenza vaccines against H5N1 ‘bird flu’ | |
BR112014008161A2 (pt) | vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas | |
Baron et al. | Recent advances in viral vectors in veterinary vaccinology | |
Bertran et al. | Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens | |
Giotis et al. | Spotlight on avian pathology: fowlpox virus | |
PE20141482A1 (es) | Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos | |
Umali et al. | Characterization of complete genome sequence of genotype VI and VII velogenic Newcastle disease virus from Japan | |
Xia et al. | Genetic and antigenic evolution of H9N2 subtype avian influenza virus in domestic chickens in southwestern China, 2013–2016 | |
RU2016112951A (ru) | Рекомбинанатные вирусы болезни марека и их применение | |
Ravikumar et al. | Vaccines against major poultry viral diseases: strategies to improve the breadth and protective efficacy | |
Rimmelzwaan et al. | Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara | |
RU2016137119A (ru) | Птичьи вирусные вакцины, которые являются стабильными в жидкой среде | |
Luke et al. | Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms | |
BR112015025898A2 (pt) | polipeptídeo, célula, ácido nucleico, vetor, vírus da varíola suína recombinante, composição, vacina, e uso de um peptídeo sinal | |
PE20221792A1 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
Hu et al. | Generation of a recombinant Newcastle disease virus expressing two foreign genes for use as a multivalent vaccine and gene therapy vector | |
Toro et al. | Avian influenza mucosal vaccination in chickens with replication-defective recombinant adenovirus vaccine | |
Nang et al. | Live attenuated H5N1 vaccine with H9N2 internal genes protects chickens from infections by both highly pathogenic H5N1 and H9N2 influenza viruses | |
Dai et al. | Infectivity and pathogenicity of Newcastle disease virus strains of different avian origin and different virulence for mallard ducklings | |
Palya et al. | Recombinant turkey herpesvirus-AI vaccine virus replication in different species of waterfowl | |
BR112022010825A2 (pt) | Vacina de vetor hvt multivalente | |
RU2018103145A (ru) | Вирус утиного энтерита и его применение | |
Wei et al. | Re‐emergence of a genotype VIII virulent Newcastle disease virus isolated from Chinese game fowl after 13 years |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |